期刊文献+

四指标联合检测对慢性丙型肝炎患者早期肾损害诊断的价值 被引量:3

The Diagnostic Value of Four Markers Monitoring for Chronic Hepatitis C Patients with Early Impairment of Renal
下载PDF
导出
摘要 目的探讨尿微量清蛋白(mALb)、尿N-乙酰β-D氨基葡萄糖苷酶(NAG)、尿转铁蛋白(TF)、尿α1-微球蛋白(α1-MG)对慢性丙型肝炎患者早期肾损害诊断的价值。方法液相终点散射免疫沉淀法检测尿转铁蛋白、放射免疫分析法测尿微量清蛋白、α1-微球蛋白、终点法测尿N-乙酰β-D氨基葡萄糖苷酶、终点法测尿肌酐。取随意尿5ml,离心后取上清液,对30例正常对照组和30例确诊为慢性丙型肝炎患者组联合以液相终点散射免疫沉淀法检测尿转铁蛋白;放射免疫分析法测尿微量清蛋白(mALb)、尿α1-微球蛋白(α1-MG);终点法测尿N-乙酰β-D氨基葡萄糖苷酶(NAG),同时用终点法测尿肌酐值。结果正常对照组尿TF/Ucr为1.02±0.58mg/mmol、mALb/Ucr为1.57±0.55mg/mmol、NAG/Ucr为6.25±2.18U/g、α1-MG/Ucr为1.65±0.56mg/mmol。慢性丙型肝炎患者尿TF、尿mALb、尿α1-MG、尿NAG均较对照组增高,并有显著性差异P<0.05,单项及2项检测尿mALb、TF、α1-MG、NAG阳性率低,联合其中3项检测阳性率较高,可达到63.3%,联合4项检测阳性率可达66.7%。4项联检的阳性率高于单项及2项检测的阳性率,并有显著性差异(P<0.05)。尿α1-MG与NAG呈显著正相关r=0.899,P<0.05,mALb与NAG、α1-MG无相关性,P>0.05,mALb与TF呈正相关r=0.701,P<0.05,TF与NAG,α1-MG均无相关性,P>0.05。结论慢性丙型肝炎患者可存在尿常规检查不能发现的肾小球和肾小管损害,检测尿mALb、TF、α1-MG、NAG是慢性丙型肝炎患者早期肾损害的敏感指标,联合3~4项指标有较高的检出率,对慢性丙肝患者肾损害的部位判断具有一定的价值。 Objective To probe into the diagnostic value of urine microlbumin,urine N - acetyl - β - D glucosaminidase,Urinar- ytransferin ,Urine α1- microglobumin for chronic hepatitis C patients with early impairment of renal. Methods Take optional centrifugal urinary 5ml respectively to measure Transterin with immunoturbidimetry, urinary microlbumin and urinary α1 - microglobumin with radio - immunoassay analyse,Urinary N - acetyl - β - D glucosaminidase and urinary creatinine were determined with endpoint for 30 normal groups and 30 chronic hepatitis C patients who were diagnosed. Results The level of urinary transferin, microlbumin,α1 - microglobumin, N - acetyl - β - D glucosaminidase,in the control were 1.02 ± 0. 58mg/mmol, 1.57 ± 0. 55mg/mmol, 1.65 ± 0. 56mg/mmol and 6.25 ± 2.18U/g. The level of urinary microlbumin, urinary transferin,α1 - microglobumin,N - acetyl - β - D glucosaminidase in chronic hepatitis C patients respectively were 4.11 ± 2.79 mg/mmol ,3.38 ± 3.06mg/mmol ,5.49 ± 4.37 mg/mmol,12.03 ± 3.78mg/mmol. Four markers in patients were significantly higher than those in controls P 〈 0. 05 . Measuring four markers together would raise the positive rate to 66.7% in chronic hepatitis C patients . The positive rate was low in single marker or two markers together. Measuring three or four markers together would raise the positive rate . A significant positive difference was noted among them. P 〈 0. 05 . A significant positive correction was noted between urinaryα1 - microglobumin and N - acetyl - β - D glucosaminidase r = 0. 899 P 〈 0. 05 , but no correction between microalbumin and α1 - microglobumin and N - acetyl - β - D glucosaminidase P 〉 0. 05. A significant positive correction was noted between urinary transferin and microlbumin r = 0. 701 P 〈 0. 05 ,but no correction between transferin and α1 - microglobumin and N - acetyl - β - D glucosaminidase P 〉 0. 05. Conclusions There are glomerular and tubuler lesions in chronic hepatitis C patients whose urine routine test were negative. The methods is sensitive to detect urinary microalbumin,Transterin,α1 - microglobumin,N - acetyl - β - D glucosaminidase. Measuring three or four markers together can get a higher positive rate. It is of value in detecting degree and situation of injury to kidney in patients with HCV chronic infection.
出处 《医学研究杂志》 2008年第3期71-74,共4页 Journal of Medical Research
关键词 慢性丙型肝炎 转铁蛋白 微量清蛋白 Α1-微球蛋白 N-乙酰β-D氨基葡萄糖苷酶 早期肾损害 Chronic hepatitis C Transferin Microlbumin α1 - microglobumin N - acetyl - β - D glucosaminidase Early impairment of renal
  • 相关文献

参考文献7

二级参考文献28

  • 1[1]Alberit A, Benvegnu L. Management of hepatitis C. J Hepatol,2003,38(suppl 1): S1014 ~ S118
  • 2[2]Booth JCL, O' Grady J, Neuberger J. Clinical guidelines on the management of hepatitis C. Gut,2001,49(Suppl Ⅰ) :S1 ~ S12
  • 3[3]Camma C, Bruno S, Schepis F, et al. Retreatment with interferon plus ribvirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. Gut, 2002,51: 864 ~ 869
  • 4[4]Chander G, Sulkowski MS, Jenckes MW. et al. Treatment of chronic hepatitis C: a systemic review. Hepatology, 2002,36 (5 suppl 1 ):S135 ~ S144
  • 5[5]DiCiommo V, Russo P, Rave L, et al. Interferon alpha in the treatment of chronic hepatits C in children: a meta-analysis. J Viral Hepat,2003, 10:210 ~ 214
  • 6[6]Fabrizi F, Dulai G, Dixit V, et al. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther,2003,18:1071 ~ 1081
  • 7[7]Kjaergard LL, Krogsgaard K, Gluud C. Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials. BMJ, 2001,323:1151 ~ 1155
  • 8[8]National Institute of Health Consensus Development Conference Statement: management of hepatitis C. Hepatology, 2002, 36: (5Suppl 1):S3 ~ 20
  • 9[9]Papatheodoridis GV, Papadimitropoulos VC, Hadziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta analysis. Aliment Pharmacol Ther,2001,15:689~ 698
  • 10[10]Poynard T, McHutchison J, Davis GL, et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology, 2000,32: 1131 ~ 1137

共引文献14052

同被引文献48

  • 1关绍晨,汤哲,吴晓光,孙菲,刁丽军,刘宏军,方向华.北京城乡老年人群代谢综合征的现况调查[J].中华老年医学杂志,2006,25(3):219-221. 被引量:51
  • 2高勇,邓庆梅,唐振华.2型糖尿病患者血清hs-CRP、IL-6和TNF-α与血管病变的关系[J].蚌埠医学院学报,2006,31(3):297-298. 被引量:7
  • 3赵凯,丁鸿娟,徐吉成.α_1-微球蛋白的生物学特性与临床应用[J].河北医药,2006,28(10):984-986. 被引量:9
  • 4赵丽娟 刘玉和 朱卫东.87例老年人血清β2微球蛋白放射免疫测定结果分析.海南医学,2002,16(7):28-28.
  • 5Martin P, Hampton KK, Walton C, et al. Microprotein- uriain type 2 diabetes mellitus from diagnosis[J]. Diabet Med,1990,7(2) :315-318.
  • 6Jung K, Pergande M, Graubaum HJ, et al. Urinary pro- teins and enzymes as early indicators of renal d3 function in chronic exposure to cadmium[J]. Clin Chem, 1993,39 (5) :757-765.
  • 7袁笑萍,郁金声,李成江,等.112例中青年及老年人血、尿β2-微球蛋白的含量测定[J].浙江医科大学学报,2009,34(4)174.
  • 8府伟灵,徐克前.临床生物化学检验[M].5版.北京:人民卫生出版社,2011:66-68.
  • 9李玉林.病理学[M].8版.北京:人民卫生出版杜,2013:129-132.
  • 10Goldstein SL, Devarajan P. Acute kidney injury in childhood: should we be worried about progression to CKD[J]. Pediatric Nephrology, 2011,23(12), 1200-1202.

引证文献3

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部